Birge Berns

624 total citations
12 papers, 525 citations indexed

About

Birge Berns is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Birge Berns has authored 12 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Birge Berns's work include Renal cell carcinoma treatment (3 papers), Renal and related cancers (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Birge Berns is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Renal and related cancers (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Birge Berns collaborates with scholars based in United Kingdom, United States and Germany. Birge Berns's co-authors include Thomas A. Puchalski, Hugh M. Davis, Uma Prabhakar, Qun Jiao, Shahneen Sandhu, Amita Patnaik, Johann S. de Bono, Brenda Tromp, Anthony W. Tolcher and David Olmos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Birge Berns

11 papers receiving 518 citations

Peers

Birge Berns

ONCOL

IMMUN

PRM

Shaivy Malik India

Tomasz Sarosiek Poland

I. Kuss United States

Nada Babović Serbia

B. Rovati Italy

Jin‐Hee Ahn South Korea

Mark Voskoboynik Australia

Gillian McNab United Kingdom

Jithendra Kini Bailur United States

Henk Mallo Netherlands

Shaivy Malik India

Birge Berns

277 ×0.9

ONCOL

251 ×0.9

IMMUN

152 ×1.2

56 ×0.7

26 ×0.6

PRM

Citations per year, relative to Birge Berns Birge Berns (= 1×) peers Shaivy Malik

Countries citing papers authored by Birge Berns

Since Specialization

Citations

This map shows the geographic impact of Birge Berns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birge Berns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birge Berns more than expected).

Fields of papers citing papers by Birge Berns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birge Berns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birge Berns. The network helps show where Birge Berns may publish in the future.

Co-authorship network of co-authors of Birge Berns

This figure shows the co-authorship network connecting the top 25 collaborators of Birge Berns. A scholar is included among the top collaborators of Birge Berns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birge Berns. Birge Berns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Berns, Birge, et al.. (2025). From text to insight: Methods for validation of NLP-extracted real-world oncology data using a human-in-the-loop electronic review tool.. Journal of Clinical Oncology. 43(16_suppl).

Kontro, Mika, Anthony S. Stein, Marja Pyörälä, et al.. (2024). Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study. Blood. 144(Supplement 1). 4265–4265. 1 indexed citations

Sandhu, Shahneen, K. Papadopoulos, Peter C.C. Fong, et al.. (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(4). 1041–1050. 228 indexed citations

Puchalski, Thomas A., Uma Prabhakar, Qun Jiao, Birge Berns, & Hugh M. Davis. (2010). Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 16(5). 1652–1661. 86 indexed citations

Bergmann, Lothar, Birge Berns, Angus Dalgleish, et al.. (2010). Investigator-initiated trials of targeted oncology agents: why independent research is at risk?. Annals of Oncology. 21(8). 1573–1578. 14 indexed citations

Larkin, James, Tom Ferguson, Lisa Pickering, et al.. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. British Journal of Cancer. 103(8). 1149–1153. 33 indexed citations

Rossi, JF, Sylvie Négrier, Nicholas D. James, et al.. (2010). A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. British Journal of Cancer. 103(8). 1154–1162. 152 indexed citations

Förster, Martin, Amita Patnaik, Shahneen Sandhu, et al.. (2010). Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2548–2548. 1 indexed citations

Schipperus, Martin R., et al.. (2009). CNTO328 (Anti-IL-6 mAb) treatment and hemoglobin (Hb) levels in renal cell cancer. Journal of Clinical Oncology. 27(15_suppl). e20648–e20648. 2 indexed citations

10.

Sandhu, Shahneen, Peter C.C. Fong, Sophia Frentzas, et al.. (2009). First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors. Journal of Clinical Oncology. 27(15_suppl). e13500–e13500. 2 indexed citations

11.

Berns, Birge, Pierre Démolis, & M. E. Scheulen. (2007). How can biomarkers become surrogate endpoints?. European Journal of Cancer Supplements. 5(9). 37–40. 5 indexed citations

12.

Berns, Birge, et al.. (1986). Mikromethode zum Nachweis erythrozyt�rer Antigene an Blutspuren. International Journal of Legal Medicine. 96(3). 163–71. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact